Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

Maines Francesca; Caffo Orazio; Veccia Antonello; Trentin Chiara; Tortora Giampaolo; Galligioni Enzo; Bria Emilio

首页> 外文期刊>Critical reviews in oncology/hematology >Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

【24h】

Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

机译：多西他赛后对转移性去势抵抗性前列腺癌患者的新药物测序

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA) improved overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) who progress after docetaxel. Although several analyses of patient cohorts receiving a sequence of two different new agents (NAs) after docetaxel have been published, no definite conclusions can be drawn regarding the best treatment strategy.

机译：背景：两种新的荷尔蒙制剂（NHAs），阿比特龙和enzalutamide，以及一种化学治疗剂，卡巴他赛（CABA）改善了多西他赛后进展的转移性去势抵抗性前列腺癌（mCRPC）患者的总体生存率（OS）。尽管已经发表了多西他赛治疗后接受两种不同新药（NA）序列治疗的患者队列的几种分析方法，但对于最佳治疗策略尚无明确的结论。

著录项

来源
《Critical reviews in oncology/hematology》 |2015年第3期|共9页
作者
Maines Francesca; Caffo Orazio; Veccia Antonello; Trentin Chiara; Tortora Giampaolo; Galligioni Enzo; Bria Emilio;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Abiraterone; Cabazitaxel; Castration-resistant; Enzalutamide; Prostate cancer; Sequence;

机译：阿比特龙;卡巴他赛;抗降钙剂;恩扎鲁胺;前列腺癌;序列;

相似文献

外文文献
中文文献
专利

1. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer [J] . Maines Francesca, Caffo Orazio, Veccia Antonello, Critical reviews in oncology/hematology . 2015,第3期

机译：多西他赛后对转移性去势抵抗性前列腺癌患者的新药物测序
2. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer [J] . Miyake Hideaki, Matsushita Yuto, Tamura Keita, International journal of clinical oncology . 2018,第3期

机译：对先前雄激素受体轴靶向剂对患者在转移阉割的前列腺癌患者的疗效没有显着影响。
3. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide [J] . Miyake Hideaki, Matsushita Yuto, Tamura Keita, Medical oncology . 2017,第12期

机译：先前雄激素受体轴靶向剂对转移阉割前列腺癌患者随后的多西紫杉醇临床活性的影响：AbiraTerone醋酸盐和依甲酰胺之间的比较评估
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421) [O] . Joseph M. Unger, Katherine Griffin, Gary W. Donaldson, 2018

机译：在一项随机III期临床试验中接受多西他赛和阿曲生坦与多西他赛和安慰剂的转移性去势抵抗性前列腺癌患者的患者报告结局（SWOG S0421）
7. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer [O] . Francesca Maines, Orazio Caffo, Antonello Veccia, 2015

机译：在转移阉割阉割前列腺癌患者中测序新剂量后的新药

Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅